No Data
Lummy Pharmaceutical Gets Drug Certificates for Heart Disease Treatment
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary has obtained a Pharmaceutical registration certificate.
On March 11, Gelonghui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical") received the drug registration certificates approved and issued by the National Medical Products Administration for injectable Nicorandil in two specifications: 2mg and 12mg. Injectable Nicorandil is primarily used for unstable angina and acute heart failure, improving coronary microcirculation, effectively reducing cardiovascular events, and significantly reducing the risk of acute coronary syndrome, providing substantial benefits to clinical patients.
Chongqing Lummy Pharmaceutical (300006.SZ): Obtained the pharmaceutical registration certificate for injectable Nicorandil (specifications: 2mg, 12mg).
On March 11, Gregor Exchange reported that Chongqing Lummy Pharmaceutical Co., Ltd. has recently received the Drug Registration Certificate for injectable Nicorandil in two specifications of 2mg and 12mg, approved by the National Medical Products Administration. Injectable Nicorandil is mainly used for unstable angina pectoris and acute heart failure, improving coronary microcirculation, effectively reducing cardiovascular events, and significantly lowering the risk of acute coronary syndrome, greatly benefiting clinical patients. Nicorandil was developed by a Sino-Japanese pharmaceutical company, with tablets and injectable forms receiving approval in Japan in 1983 and 1993 respectively.
Chongqing Lummy Pharmaceutical (300006.SZ) plans to indirectly invest 40 million yuan in the Eastna Medical Fund to布局 the Medical health field.
Chongqing Lummy Pharmaceutical (300006.SZ) announced that the company intends to participate as a limited partner with its own funds of 40 million yuan ...
Chongqing Lummy Pharmaceutical (300006.SZ) plans to invest in Guangdong Dongna Collaborative Industrial Investment Partnership.
On March 5th, Gelonghui reported that Chongqing Lummy Pharmaceutical (300006.SZ) announced it aims to further optimize its investment structure, enhance investment value, and accelerate the layout of high-barrier and high-growth strategic segments in the pharmaceutical health Industry Chain. The company intends to sign a "Partnership Agreement" with Demoh Consulting (Shenzhen) Co., Ltd., Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., CONSUN PHARMA, Ding Jun, and Zhang Shian to invest its own funds in Guangdong Dongna Collaborative Industry Investment Partnership (Limited Partnership). After this investment is completed, the total capital contribution of the partnership will be 91 million RMB, with the company participating as a partner in this partnership.
Is Chongqing Lummy Pharmaceutical (SZSE:300006) Using Too Much Debt?
Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) Popularity With Investors Under Threat As Stock Sinks 28%
